Your browser doesn't support javascript.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
Supasa, Piyada; Zhou, Daming; Dejnirattisai, Wanwisa; Liu, Chang; Mentzer, Alexander J; Ginn, Helen M; Zhao, Yuguang; Duyvesteyn, Helen M E; Nutalai, Rungtiwa; Tuekprakhon, Aekkachai; Wang, Beibei; Paesen, Guido C; Slon-Campos, Jose; López-Camacho, César; Hallis, Bassam; Coombes, Naomi; Bewley, Kevin R; Charlton, Sue; Walter, Thomas S; Barnes, Eleanor; Dunachie, Susanna J; Skelly, Donal; Lumley, Sheila F; Baker, Natalie; Shaik, Imam; Humphries, Holly E; Godwin, Kerry; Gent, Nick; Sienkiewicz, Alex; Dold, Christina; Levin, Robert; Dong, Tao; Pollard, Andrew J; Knight, Julian C; Klenerman, Paul; Crook, Derrick; Lambe, Teresa; Clutterbuck, Elizabeth; Bibi, Sagida; Flaxman, Amy; Bittaye, Mustapha; Belij-Rammerstorfer, Sandra; Gilbert, Sarah; Hall, David R; Williams, Mark A; Paterson, Neil G; James, William; Carroll, Miles W; Fry, Elizabeth E; Mongkolsapaya, Juthathip.
  • Supasa P; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Zhou D; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Dejnirattisai W; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Liu C; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
  • Mentzer AJ; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Ginn HM; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • Zhao Y; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Duyvesteyn HME; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Nutalai R; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Tuekprakhon A; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Wang B; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Paesen GC; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Slon-Campos J; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • López-Camacho C; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Hallis B; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Coombes N; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Bewley KR; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Charlton S; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Walter TS; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Barnes E; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
  • Dunachie SJ; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Centre For Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand
  • Skelly D; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Lumley SF; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Baker N; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Shaik I; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Humphries HE; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Godwin K; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Gent N; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Sienkiewicz A; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Dold C; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Levin R; Worthing Hospital, Worthing, UK.
  • Dong T; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Ox
  • Pollard AJ; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Knight JC; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Klenerman P; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
  • Crook D; Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Lambe T; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Clutterbuck E; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Bibi S; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Flaxman A; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Bittaye M; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Belij-Rammerstorfer S; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Gilbert S; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Hall DR; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • Williams MA; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • Paterson NG; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • James W; Sir William Dunn School of Pathology University of Oxford, Oxford, UK.
  • Carroll MW; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Fry EE; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Mongkolsapaya J; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK; Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Dean Office for Researc
Cell ; 184(8): 2201-2211.e7, 2021 04 15.
Article in English | MEDLINE | ID: covidwho-1086820
ABSTRACT
SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of the pandemic and error-prone virus replication is leading to the appearance of mutant viruses and potentially escape from antibody responses. Variant B.1.1.7, now dominant in the UK, with increased transmission, harbors 9 amino acid changes in the spike, including N501Y in the ACE2 interacting surface. We examine the ability of B.1.1.7 to evade antibody responses elicited by natural SARS-CoV-2 infection or vaccination. We map the impact of N501Y by structure/function analysis of a large panel of well-characterized monoclonal antibodies. B.1.1.7 is harder to neutralize than parental virus, compromising neutralization by some members of a major class of public antibodies through light-chain contacts with residue 501. However, widespread escape from monoclonal antibodies or antibody responses generated by natural infection or vaccination was not observed.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal / Antibodies, Viral Type of study: Observational study Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Cell Year: 2021 Document Type: Article Affiliation country: J.cell.2021.02.033

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Antibodies, Monoclonal / Antibodies, Viral Type of study: Observational study Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Cell Year: 2021 Document Type: Article Affiliation country: J.cell.2021.02.033